Biotech Values

[iwfal]

eypt is ahead in the NI trial, and there is no way ocul gets approval without successful sol-r IMO despite what they say about filing just based on sol-1

Yeah, this is the point often missed by the OCUL longs. There weren't any huge safety issues, but there were clearly a large number of more minor safety issues compared to eylea. Probably mostly related to having a high dose of a TKI (much broader activity than VEGF mab), so potentially getting worse on redosing - which is in SOL-R, not SOL-1. Had it been cleaner, and with a compelling clinical need... then sure, would have been likely to garner approval on SOL-1 alone. But this is not the case, so... .